Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Li Tang is an Associate Professor with tenure at École polytechnique fédérale de Lausanne (EPFL), affiliated with the Institute of Bioengineering (IBI) and the Institute of Materials Science and Engineering (IMX) within the School of Engineering (STI). She leads the Laboratory of Biomaterials for Immunoengineering, focusing on developing innovative strategies at the intersection of immunology, materials science, and cancer therapy. Her work bridges fundamental research and clinical translation, with multiple ongoing clinical trials based on CAR-T cell therapies developed in her lab. B.S. in Chemistry, Peking University (2003–2007) Ph.D. in Materials Science and Engineering, University of Illinois at Urbana-Champaign (2007–2012) Postdoctoral Fellow, MIT (2013–2016) Her research lies at the forefront of immunoengineering, integrating chemical, metabolic, and mechanical approaches to modulate immune responses. Key areas include cancer immunotherapy, immune metabolism, mechano-immunology, and biomaterials. She investigates how physical and biochemical cues can reprogram T cells, overcome exhaustion, and enhance tumor targeting. Her work emphasizes multidimensional immunity-disease interactions, aiming to develop safer and more effective therapies for cancer and autoimmune diseases. The recent publications highlight a strong trend in engineering immune cells (especially CAR-T) for enhanced durability and function, using advanced biomaterials and metabolic reprogramming. There is a clear focus on overcoming challenges in solid tumors, modulating the tumor microenvironment, and translating findings into clinical applications. The use of nanoparticle delivery, single-cell analysis, and biomechanical cues are recurring themes across her work. Notable scientific awards include: Friedrich Miescher Award (2025) ERC Starting Grant (2018) MIT TR35 Innovators Under 35 (China Region, 2020) Nano Research Young Innovator Award (2018) Biomaterials Science Emerging Investigator (2019) Materials Horizons Emerging Investigator (2020) Li Tang actively mentors PhD students across multiple doctoral programs (EDBB, EDMS, EDMX) and has advised numerous graduates who have gone on to prestigious postdoctoral and faculty positions. She is involved in significant research grants, including an Innosuisse project with Novochizol SA, and her lab is supported by competitive funding. She teaches core courses such as Immunoengineering and Next-Generation Biomaterials, shaping the next generation of scientists. Her lab fosters interdisciplinary collaboration and innovation, with active projects in chemical, metabolic, and mechanical immunoengineering, as well as CAR-T cell development. She is the Principal Investigator of the Tang Lab, which includes postdoctoral fellows, PhD students, and technical staff. The lab is actively recruiting and has a strong publication and clinical translation record. Tang Lab is also involved in multiple MA/BA training projects and promotes student engagement in cutting-edge research. The lab’s discoveries are being translated into clinical trials, reflecting a strong commitment to translational science.
Dr. Christina Leslie is a Research Professor and Member of the Computational & Systems Biology Program at Memorial Sloan Kettering Cancer Center (MSK). She leads an active research laboratory focused on developing computational approaches to understand complex biological systems. Dr. Leslie earned her PhD from the University of California, Berkeley and has established herself as a leading computational biologist in cancer research and immunology. Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center Gerstner Sloan Kettering Graduate School of Biomedical Sciences Dr. Leslie's research focuses on developing novel computational methods to study cellular biological systems from a global and data-driven perspective. Her lab exploits diverse high-throughput functional and genomic data to understand molecular networks underlying fundamental cellular processes, including transcription regulation, pre-mRNA processing, signaling, and post-transcriptional gene silencing. Her algorithmic methods draw heavily on machine learning to build accurate predictive models from noisy and high-dimensional biological data. Key areas of interest include modeling cell-type specific transcriptional programs and dissecting co- and post-transcriptional regulation, particularly microRNA-mediated gene regulation. Analysis of Dr. Leslie's publication record over the last five years reveals a strong focus on computational approaches to cancer genomics, immunology, and epigenetics. Her work bridges multiple disciplines, with a particular emphasis on developing machine learning methods to interpret complex biological data. The publications demonstrate increasing sophistication in integrating multiple data types (genomic, transcriptomic, epigenomic) to understand cancer biology and immune responses. Recent work shows a growing emphasis on single-cell technologies and spatial analysis of tumor microenvironments. Introduction of string kernel methodology for SVM classification of biological sequences Development of algorithms for predictive modeling of gene regulation First systems-level analyses of competition between microRNAs and between target transcripts Dr. Leslie actively mentors numerous graduate students and research associates, with current lab members including Vianne Gao, Alireza Karbalaghareh, Erik Ladewig, and several others. Her lab has received significant research funding to support their work on computational approaches to cancer biology and immunology. The Leslie Lab maintains close collaborations with multiple experimental groups at MSK, facilitating the translation of computational insights into biological understanding. The Leslie Lab operates within the Computational & Systems Biology Program at MSK, with strong ties to both the research and clinical missions of the institution. The lab maintains state-of-the-art computational infrastructure for analyzing large-scale genomic and proteomic datasets and collaborates extensively with wet-lab researchers to validate computational predictions experimentally.
Bérénice Benayoun, PhD is an Associate Professor at the USC Leonard Davis School of Gerontology , with secondary appointments in the Department of Molecular and Computational Biology (USC Dornsife College of Letters, Arts and Sciences) and the USC Norris Comprehensive Cancer Center . Her research bridges aging biology , epigenetics , and sex differences using vertebrate models like the African turquoise killifish and machine learning . Education : École Normale Supérieure (BSc, MSc), Paris Diderot-Paris 7 University (PhD in Genetics and Cell Biology) Her lab investigates epigenome and transcriptome remodeling during aging , focusing on how biological sex influences these processes. Key themes include inflamm-aging , genomic instability , and immune senescence , with applications in neurodegeneration and reproductive longevity . Recent publications highlight sex-dimorphic gene regulation in neutrophils , macrophages , and brain aging , alongside novel insights into transposable elements and MOTS-c mitochondrial signaling . She pioneers the use of single-cell transcriptomics and multi-omics in aging research. Scientific awards include: 2024 Vincent Cristofalo Rising Star in Aging Research Award 2023 AGHE Rising Star Early Career Faculty Award 2023 USC Mentoring Award 2023 Rising Star in Reproductive Biology 2021 Nathan Shock New Investigator Award 2019 Rosalind Franklin Young Investigator Award Her editorial roles include Geroscience , Translational Medicine of Aging , and eLife . She mentors students across PhD programs in Biology of Aging , Neuroscience , and Molecular Medicine , as well as Master's and undergraduate trainees.
Prof. Dr. Kathrin Schumann is an Assistant Professor at the Technical University of Munich (TUM), leading the 'Engineering Immune Cells for Therapy' group within the TUM School of Medicine and Health. Her research focuses on CRISPR-based engineering of human immune cells to develop novel therapies for autoimmune and tumor diseases. She holds a doctorate from the Max Planck Institute of Biochemistry and has conducted postdoctoral research at the University of California, San Francisco, under Professors Alex Marson and Jeffrey Bluestone. Dr. Schumann’s academic career includes a Presidential Postdoc Fellowship at Novartis (Basel) and a tenure-track appointment at TUM since 2018. Her work emphasizes genomic editing of T cells to study gene function and improve cell therapy safety. Key research themes include CRISPR-mediated gene silencing, T cell receptor engineering, and HIV-host interaction studies. Education: Bachelor/Master in Biochemistry, University of Tübingen PhD, Max Planck Institute of Biochemistry (Martinsried) Postdoc, University of California, San Francisco (UCSF) Her research has yielded breakthroughs in CRISPR applications for T cell therapy, including PD-1 disruption to enhance anti-tumor efficacy and targeted editing of T cell receptors. Awards include a DFG research grant (2016). Notable achievements include the development of CRISPR ribonucleoprotein platforms for primary T cells and insights into metabolic checkpoints in T cell exhaustion. Her lab collaborates globally to translate CRISPR-based discoveries into clinical therapies.
Martin Jastroch is a Professor at Stockholm University's Department of Molecular Biosciences, The Wenner-Gren Institute. His research focuses on the physiology and molecular mechanisms of energy metabolism from organism to molecule level. His primary research interests include: Energy metabolism physiology and molecular mechanisms Obesity and metabolic aspects Adipose tissue biology Mitochondrial mechanisms Thermogenesis and brown fat function Metabolic regulation in health and disease Professor Jastroch's research spans multiple disciplines, connecting molecular mechanisms with whole-organism physiology. His work on mitochondrial bioenergetics and thermogenesis has contributed significantly to understanding how energy metabolism is regulated across different biological scales. Recent publications show a growing interest in the evolutionary aspects of thermogenesis and the role of brown adipose tissue in metabolic diseases, with particular focus on UCP1 function, mitochondrial adaptations, and metabolic reprogramming in disease states. His scientific contributions include important findings on: UCP1 (Uncoupling Protein 1) function and regulation Mitochondrial bioenergetics in different tissue types Evolutionary aspects of mammalian thermogenesis Metabolic regulation in obesity and related disorders Links between mitochondrial dysfunction and neurodegenerative diseases Professor Jastroch leads 'Group Jastroch' at Stockholm University, where his team investigates the complex interplay between cellular energy metabolism and whole-body physiology, with implications for understanding and treating metabolic disorders.
Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.
Kunihiko Kaneko is a Professor at the Niels Bohr Institute, University of Copenhagen, with a distinguished career in theoretical biophysics and complex systems. He received his PhD and MSc in Physics from the University of Tokyo, and has held leadership roles at the Universal Biology Institute and Center for Complex Systems Biology. PhD Physics, 1984 - University of Tokyo MSc Physics, 1981 - University of Tokyo His research spans five primary areas: Universal Biology, Evolutionary Constraints, Ecosystem Dynamics, Neural Cognition, and Universal Anthropology. He has published extensively on multi-level consistency principles, dimensional reduction in biological systems, and reciprocity between robustness and plasticity across scales. Recent publications show strong focus on microbial ecosystems (2025), evolutionary game theory (2025), neural modular architectures (2024), and dimensional reduction in cellular systems (2024). His work bridges physics and biology through dynamical systems theory applied to diverse phenomena from protocells to human societies.
Prof. Dr. Soeren Lienkamp is an Assistant Professor at the Institute of Anatomy , Faculty of Medicine , University of Zurich . His work bridges digital education and genetic research , focusing on enhancing medical teaching through innovative formats. Research Interests : Genetics, developmental biology, kidney disease modeling, CRISPR applications, digital medical education, and advanced microscopy. Methodologies : Combines Xenopus tropicalis models, deep learning , and bioengineering to study genetic kidney disorders and improve diagnostic tools. Publication Trends : His recent articles highlight predictable genome editing , 3D imaging technologies , and mechanistic insights into kidney and eye development. Earlier works focus on ciliary function , Wnt signaling , and metabolic stress in renal cells.
Wen Xue is a Professor at UMass Chan Medical School, affiliated with the RNA Therapeutics Institute within the T.H. Chan School of Medicine. She holds multiple additional roles across departments such as the Program in Molecular Medicine, Cancer Biology, and Biochemistry and Molecular Biotechnology at the Morningside Graduate School of Biomedical Sciences. Her research focuses on developing genetic models for liver and lung cancer using CRISPR/Cas9 and RNAi tools. Key areas include CRISPR-mediated genome editing for cancer gene discovery, KRAS inhibition mechanisms, and miRNA networks in lung cancer. She has secured grants from NIH, American Cancer Society, and others. Awards include the NIH Director’s New Innovator Award and Lung Cancer Research Foundation grants. Her lab actively recruits postdoctoral researchers and offers rotation projects in CRISPR technology and cancer biology. Education: B.S. and M.S. in Biochemistry from Nanjing University; Ph.D. in Biochemistry from State University of New York, Stony Brook. Research Interests: Wen Xue’s lab employs CRISPR tools to accelerate cancer gene validation and therapeutic target identification. Projects include: CRISPR-based liver cancer gene correction and oncogene deletion studies. Investigating KRAS inhibition resistance via RNAi and CRISPR in lung cancer models. Characterizing miRNA networks using TCGA data to identify therapeutic miRNA candidates. Her work bridges functional genomics with precision medicine, emphasizing in vivo and in vitro platforms. Publications: Over 100 peer-reviewed articles, including high-impact studies on CRISPR applications in gene therapy and cancer modeling. Recent work explores prime editing, base editing, and viral/non-viral delivery systems for lung diseases. Grants & Awards: NIH grants (P01HL131471, DP2HL137167), American Cancer Society (RSG-16-093), and industry partnerships like the Cystic Fibrosis Foundation. Collaborations include projects on CFTR mutation repair and AAV vector development. Labs/Teams: Xue Lab focuses on cancer genetics and gene editing, with interdisciplinary collaborations in molecular medicine and bioengineering. Ongoing projects aim to translate CRISPR-based therapies into clinical applications.
